GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Cyclically Adjusted PB Ratio

Inotiv (Inotiv) Cyclically Adjusted PB Ratio : 0.84 (As of Apr. 28, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Inotiv Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Inotiv's current share price is $4.05. Inotiv's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $4.84. Inotiv's Cyclically Adjusted PB Ratio for today is 0.84.

The historical rank and industry rank for Inotiv's Cyclically Adjusted PB Ratio or its related term are showing as below:

NOTV' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.29   Med: 0.93   Max: 41.34
Current: 0.84

During the past years, Inotiv's highest Cyclically Adjusted PB Ratio was 41.34. The lowest was 0.29. And the median was 0.93.

NOTV's Cyclically Adjusted PB Ratio is ranked better than
73.28% of 131 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.98 vs NOTV: 0.84

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Inotiv's adjusted book value per share data for the three months ended in Dec. 2023 was $9.855. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.84 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Inotiv Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Inotiv's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Cyclically Adjusted PB Ratio Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.55 3.83 20.90 4.73 0.66

Inotiv Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.30 1.06 1.09 0.66 0.76

Competitive Comparison of Inotiv's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Inotiv's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inotiv's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Inotiv's Cyclically Adjusted PB Ratio falls into.



Inotiv Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Inotiv's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.05/4.84
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inotiv's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Inotiv's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=9.855/129.4194*129.4194
=9.855

Current CPI (Dec. 2023) = 129.4194.

Inotiv Quarterly Data

Book Value per Share CPI Adj_Book
201403 1.048 99.695 1.360
201406 1.072 100.560 1.380
201409 1.034 100.428 1.332
201412 1.064 99.070 1.390
201503 1.090 99.621 1.416
201506 1.264 100.684 1.625
201509 1.177 100.392 1.517
201512 1.107 99.792 1.436
201603 1.075 100.470 1.385
201606 1.022 101.688 1.301
201609 0.774 101.861 0.983
201612 0.780 101.863 0.991
201703 0.842 102.862 1.059
201706 0.873 103.349 1.093
201709 0.902 104.136 1.121
201712 0.909 104.011 1.131
201803 0.920 105.290 1.131
201806 0.976 106.317 1.188
201809 1.059 106.507 1.287
201812 1.046 105.998 1.277
201903 0.997 107.251 1.203
201906 0.981 108.070 1.175
201909 1.016 108.329 1.214
201912 0.956 108.420 1.141
202003 0.910 108.902 1.081
202006 0.839 108.767 0.998
202009 0.690 109.815 0.813
202012 0.668 109.897 0.787
202103 0.633 111.754 0.733
202106 5.603 114.631 6.326
202109 6.599 115.734 7.379
202112 24.273 117.630 26.706
202203 24.226 121.301 25.847
202206 24.055 125.017 24.902
202209 14.078 125.227 14.549
202212 10.966 125.222 11.334
202303 10.635 127.348 10.808
202306 10.707 128.729 10.764
202309 10.442 129.860 10.407
202312 9.855 129.419 9.855

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inotiv  (NAS:NOTV) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Inotiv Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Inotiv's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (Inotiv) Business Description

Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Executives
John Gregory Beattie officer: Chief Operating Officer C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett officer: Chief Commercial Officer 250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter officer: SVP, Gen. Counsel & Secretary 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz director, officer: Chief Strategy Officer 19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman director 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure director, officer: President and CEO C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor officer: Chief Financial Officer 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp officer: Chief Human Resources Officer 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford officer: Chief Human Resources Officer 1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff director 535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman officer: VP-Finance & Corp. Controller 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown director 250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg director 660 MADISON AVENUE, NEW YORK NY 10065